Boston Scientific Corp
I · KI-Analyse
Kurzfassung
Boston Scientific designs and sells specialized medical equipment that doctors use during minimally-invasive procedures — think catheters, stents, implants, and electronic devices that treat conditions in the heart, digestive tract, urinary system, and nervous system [Boston Scientific]. Their products help cardiologists open blocked arteries, urologists treat bladder problems, and pain specialists manage chronic pain through implanted nerve stimulators [Boston Scientific].
Boston Scientific is a $84.4 billion medical device company that makes products for heart procedures, digestive system treatments, urology, and pain management [Yahoo Finance]. The company reported strong revenue growth of 19.9% year-over-year and recently announced a $2 billion share buyback alongside a $1.5 billion investment in MiRus, a company developing a new heart valve technology [Yahoo Finance]. Recent clinical trial success with its SEISMIQ 4CE device for treating severely calcified heart arteries positions the company well in a challenging cardiac niche [Simply Wall St].
Boston Scientific is financially stable with strong cash generation, though debt levels are moderate and returns on invested capital remain below 10% [Yahoo Finance].
Sentinellis-Score
6.3/10
Moderate concerns
Marktkapitalisierung
$84.4B
Umsatz (12 Monate)
$20.1B
II · Aktuelle Nachrichten
Was den Kurs bewegt hat
6 stories · ranked by relevance
- macro2026-05-20
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
Simply Wall St
- macro2026-05-20
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Yahoo Finance
- macro2026-05-20
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Yahoo Finance
- macro2026-05-19
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Yahoo Finance
- macro2026-05-19
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Yahoo Finance
- macro2026-05-18
Boston Scientific announces strategic investment in MiRus LLC
Yahoo Finance
Premium · kostenlos mit jedem Konto
The company's stock underperformed in Q1 2026 as part of broader market weakness driven by geopolitical conflicts, private credit concerns, government shutdown, and AI uncertainty, with Boston Scientific being among top holdings in funds that lost over 11% during the period [Yahoo Finance].
Risiken
4
Chancen
6
Führung
10
19 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.
Vollständige Boston Scientific Corp-Analyse freischalten
Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.
- 4 Risiken und 6 Chancen — jeweils mit Quelle
- Über 100 Finanzkennzahlen mit Charts und Vergleichen
- Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
- Führungsteam und Vergütung
- PDF-Export für offline
III · Ähnliche Unternehmen
Das könnte Sie auch interessieren
Same sector · Healthcare or comparable health
Auf Ihre Watchlist setzen?